SCHEMBL20134774

SCHEMBL20134774

Cc1ccc(-n2cnc(C3CCN(C(=O)c4ccc(C5(C)NC(=O)NC5=O)cc4)CC3)c2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UBE2M P61081 1/20 0.39
DCUN1D1 Q96GG9 1/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
MAPK7 Q13164 1/20 0.39
MMP2 P08253 1/20 0.37
MMP9 P14780 1/20 0.37
CRBN Q96SW2 2/20 0.37
HSD11B1 P28845 1/20 0.36
MGLL Q99685 1/20 0.36
PAK1 Q13153 1/20 0.35
PKM P14618 1/20 0.35
KDM4E B2RXH2 1/20 0.35
POLB P06746 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
LMNA P02545 1/20 0.35
GABRD O14764 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRA5 P31644 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20134773 1.00 UBE2M (0.39) UBE2MDCUN1D1MEN1KMT2AMAPK7
SCHEMBL20135476 0.88 ADAM17 (0.39) UBE2MDCUN1D1MEN1KMT2AMAPK7
SCHEMBL20135479 0.88 ADAM17 (0.39) UBE2MDCUN1D1MEN1KMT2AMAPK7
SCHEMBL20135363 0.84 UBE2M (0.39) UBE2MDCUN1D1MEN1KMT2AMAPK7
SCHEMBL20135362 0.84 UBE2M (0.39) UBE2MDCUN1D1MEN1KMT2AMAPK7
SCHEMBL20134970 0.80 MGLL (0.39) UBE2MDCUN1D1MEN1KMT2AMAPK7
SCHEMBL20134973 0.80 MGLL (0.39) UBE2MDCUN1D1MEN1KMT2AMAPK7
SCHEMBL20791693 0.79 UBE2M (0.40) UBE2MDCUN1D1MEN1KMT2AMAPK7
SCHEMBL20791691 0.79 UBE2M (0.40) UBE2MDCUN1D1MEN1KMT2AMAPK7
SCHEMBL20791692 0.79 ABL1 (0.41) UBE2MDCUN1D1MEN1KMT2AMAPK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 UBE2M 2697/4885DCUN1D1 3076/4885MEN1 3735/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 UBE2M 2592/4885DCUN1D1 3027/4885MEN1 2913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.